Irena L. Shlivko

Irena L. Shlivko

Auto-generated profile, based on publicly available information

Irena L. Shlivko

Privolzhsky Research Medical University

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2012 in Skin Research and Technology
Verified
Journal Article
Closed access
PDF file
ISI. L. Shlivko
I. L. Shlivko
GPG. A. Petrova
G. A. Petrova
MZM. V. Zor'Kina
M. V. Zor'Kina
OTO. E. Tchekalkina
O. E. Tchekalkina
MFM. S. Firsova
M. S. Firsova
EDE. V. Donchenko
E. V. Donchenko

16 January 2015 in Skin Research and Technology
Verified
Journal Article
Closed access
PDF file
ISI. L. Shlivko
I. L. Shlivko
Mikhail KirillinMikhail Kirillin
Mikhail Kirillin
EDE. V. Donchenko
E. V. Donchenko
DED. O. Ellinsky
D. O. Ellinsky
OGO. E. Garanina
O. E. Garanina
VKV. A. Kamensky
V. A. Kamensky

1 July 2013 in Skin Research and Technology
Verified
Journal Article
Closed access
ISI. L. Shlivko
I. L. Shlivko
VKV. A. Kamensky
V. A. Kamensky
EDE.V. Donchenko
E.V. Donchenko
PAP. Agrba
P. Agrba

30 July 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
OGO. E. Garanina
O. E. Garanina
ISIgor Samoylenko
Igor Samoylenko
ISI. L. Shlivko
I. L. Shlivko
IKI. A. Klemenova
I. A. Klemenova
MNM. S. Neznakhina
M. S. Neznakhina
LDL. V. Demidov
L. V. Demidov
Introduction.Currently, numerous studies are published by authors of different countries to demonstrate the effectiveness of noninvasive methods in the diagnosis of melanoma.Methods.A systematic search was conducted independently in the databases PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) until April 2020 according to certain inclusion criteria. Data extraction was carried out independently, followed by generalization using descriptive tables. Due to the heterogeneity of the included studies and the impossibility of carrying out a meta-analysis in view of this, we performed a narrative description.Results.A total of 765 potential publications for inclusion were found and checked, of which 53 were included. By design, the studies were assigned to studies of simultaneous design – 40, to randomized clinical trials – 7, to meta-analysis – 6. Data in the included publications on 76802 skin neoplasms were reported, of which 9070 were melanomas. The extracted data were summarized in descriptive tables.Conclusion.With continuing technological progress, the development of noninvasive imaging technologies in the diagnosis of skin melanoma should follow the path of cost-effective, simple and accurate diagnosis.

1 January 2020 in Sovremennye tehnologii v medicine
Verified
Journal Article
Open access
AMAnna Mironycheva
Anna Mironycheva
MKM.Yu. Kirillin
M.Yu. Kirillin
AKA.V. Khilov
A.V. Khilov
AMA.Sh. Malygina
A.Sh. Malygina
DKD.A. Kurakina
D.A. Kurakina
SGS.V. Gamayunov
S.V. Gamayunov
The aim of the study was to assess the capabilities of combined application of dual-wavelength fluorescence visualization and contactless skin thermometry during photodynamic therapy monitoring (PDT) of basal cell cancer. Materials and Methods. The study was performed at the University Clinic of Privolzhsky Research Medical University (Nizhny Novgorod). Nine clinically, dermatoscopically, and histologically verified foci of basal cell skin cancer were exposed to PDT sessions (wavelength of 662 nm, light dose density of 150 J/cm(2)) with systemic application of chlorin-based photosensitizer Fotoditazin. A semiconductor laser system Latus-T (Russia) was employed for irradiation. Dual-wavelength fluorescence visualization and contactless thermometry with an IR pyrometer were used to monitor the PDT sessions. Results. The PDT sessions of nine foci of basal cell cancer were carried out under the control of fluorescence imaging and contactless thermometry. Photosensitizer photobleaching in all foci amounted to 40% signifying a percent of photosensitizer involved in the photodynamic reaction. It has been shown that the combined employment of dual-wavelength fluorescence monitoring and contactless thermometry during the PDT of basal cell skin cancer allows oncologists to control simultaneously the degree of photosensitizer photobleaching and the depth of the photodynamic effect in tissues, the extent of involving the mechanisms associated with hyperthermia as well as the correctness of the procedure conducting. In the course of 9-month dynamic follow-up after the treatment, no clinical and dermatoscopic signs of recurrence were found. Conclusion. A bimodal control of PDT enables the assessment of the correctness and efficacy of the procedure performance. The contactless control of tissue heating allows ensuring the temperature mode for hyperthermia realization, while the fluorescence monitoring makes it possible to evaluate the accumulation of the photosensitizer in the tumor and the depth of the PDT action as well as to predict the procedure efficacy based on the photobleaching data. The complementary use of these techniques allows the adjustment of the mode directly in the course of the PDT procedure. The acquisition of the sufficient statistical data on the combined monitoring will result in the development of a novel PDT protocol.

15 December 2021 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
ISIrena L. Shlivko
Irena L. Shlivko
OGOxana E. Garanina
Oxana E. Garanina
EAElena V. Artamonova
Elena V. Artamonova
IGInna P. Ganshina
Inna P. Ganshina
LZLiudmila Zhukova
Liudmila Zhukova
DFDaria A. Filonenko
Daria A. Filonenko
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Society of Clinical Oncology and dermatovenerologists. PIK3CA mutation is a poor prognostic factor for HR+ HER2- metastatic breast cancer. Alpelisib demonstrates efficacy in patients with PIK3CA mutation, but treatment might be associated with adverse events that include rash. All-grade rash was reported in 35.6% patients in SOLAR-1 trial (n=284). According to the published real-world data, for Russian population (n=19) all-grade rash was reported for 37% patients. The consensus contains practical recommendation on management of patients with rash of different grade.